Vijaya Diagnostic Centre quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	231	188	+22.8%
EBITDA	98.5	73.5	+34.0%
EBITDA margin	42.7%	39.1%	+3.6 pts
Profit before tax	70.9	52.2	+35.9%
Net profit	53.1	38.6	+37.6%
EPS	₹5.16	₹3.76	+37.2%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	231	219	205	202	188	173	169	183	156	155	133	139	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.5	2.4	5.1	6.2	7.0	5.5	4.7	4.5	3.6	3.3	5.1	6.8
	240	222	210	208	195	179	174	187	160	158	138	146
	25.6	24.9	24.0	24.3	21.4	22.2	20.9	23.0	18.8	18.8	16.0	16.3
	37.5	33.8	33.0	32.3	31.6	28.4	28.6	27.8	27.4	24.5	23.0	21.8
	11.0	9.3	8.6	7.8	7.5	7.2	6.8	6.5	6.3	6.2	6.1	5.9
	25.1	24.3	24.3	22.3	20.9	18.8	18.3	16.8	16.6	16.3	14.5	13.7
	69.4	65.1	62.1	63.2	61.5	53.8	52.4	56.1	48.9	48.8	41.4	43.3
	169	158	152	150	143	130	127	130	118	115	101	101
	98.5	95.5	86.1	81.8	73.5	68.9	67.1	76.0	61.2	63.1	52.3	57.4
	73.4	71.2	61.7	59.6	52.6	50.0	48.8	59.1	44.6	46.8	37.8	43.7
Profit
	70.9	64.3	58.2	58.0	52.2	48.4	46.7	57.2	41.9	43.9	36.8	44.6
	0.0	0.0	0.0	0.0	0.0	−1.0	0.0	0.0	0.0	0.0	−2.1	0.0
	70.9	64.3	58.2	58.0	52.2	47.4	46.7	57.2	41.9	43.9	34.8	44.6
	16.6	14.8	11.7	12.6	11.6	9.4	9.3	12.8	9.6	8.2	9.2	8.7
	1.3	1.5	3.4	2.1	2.0	3.1	2.1	2.2	0.8	2.0	−0.5	2.3
	17.8	16.3	15.0	14.7	13.6	12.5	11.4	15.1	10.4	10.2	8.8	11.0
	53.1	47.9	43.2	43.3	38.6	34.9	35.3	42.1	31.5	33.7	26.0	33.6
	53.1	47.9	43.2	43.3	38.6	34.9	35.3	42.1	31.5	33.7	26.0	33.6
	0.2	0.5	−0.0	0.3	−0.1	0.1	−0.0	−0.0	−0.0	−0.3	0.0	0.0
	53.3	48.4	43.1	43.6	38.5	35.0	35.3	42.1	31.5	33.4	26.0	33.6
	53.1	47.9	43.2	43.3	38.3	34.6	35.2	41.9	31.3	33.5	25.8	33.3
	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.2	0.2	0.2	0.2	0.3
Per share
	₹5.16	₹4.66	₹4.20	₹4.21	₹3.76	₹3.38	₹3.42	₹4.09	₹3.06	₹3.27	₹2.53	₹3.26
	₹5.15	₹4.65	₹4.19	₹4.20	₹3.75	₹3.37	₹3.42	₹4.08	₹3.05	₹3.26	₹2.52	₹3.25
Other comprehensive income — detail
	0.2	0.5	−0.0	0.3	−0.1	0.1	—	—	—	—	—	—
	0.2	0.6	−0.0	0.4	−0.1	0.1	−0.0	−0.0	−0.0	−0.3	0.1	0.1
	0.1	0.2	−0.0	0.1	−0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.0	−0.1	0.0	0.0
	53.3	48.4	43.1	43.6	38.3	34.7	35.1	41.9	31.3	33.2	25.9	33.4
	0.0	0.0	0.0	0.0	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.3
Per share — as-filed variants
	₹5.16	₹4.66	₹4.20	₹4.21	₹3.76	₹3.38	₹3.42	₹4.09	₹3.06	₹3.27	₹2.53	₹3.26
	₹5.15	₹4.65	₹4.19	₹4.20	₹3.75	₹3.37	₹3.42	₹4.08	₹3.05	₹3.26	₹2.52	₹3.25
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	205	194	181	177	167	151	148	160	137	136	117	123
	88.9%	88.6%	88.3%	87.9%	88.6%	87.2%	87.7%	87.4%	88.0%	87.9%	88.0%	88.2%
Adjusted (ex-exceptional items) — derived
	70.9	64.3	58.2	58.0	52.2	48.4	46.7	57.2	41.9	43.9	36.8	44.6
	0.0	0.0	0.0	0.0	0.0	−1.0	0.0	0.0	0.0	0.0	−2.1	0.0
	53.1	47.9	43.2	43.3	38.6	35.6	35.3	42.1	31.5	33.7	27.5	33.6
	₹5.16	₹4.66	₹4.20	₹4.21	₹3.76	₹3.45	₹3.42	₹4.09	₹3.06	₹3.27	₹2.68	₹3.26

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIJAYA₹1,464.20

Vijaya Diagnostic Centre Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTHYROCARE METROPOLIS LALPATHLAB RAINBOW POLYMED PFIZER ONESOURCE KIMSMcap ₹15,066 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	138.9	132.7	155.2	156.2	182.9	169.0	173.2	188.1	201.6	205.2	219.4	231.0
Other Income	6.8	5.1	3.3	3.6	4.5	4.7	5.5	7.0	6.2	5.1	2.4	8.5
Total Income	145.6	137.8	158.5	159.8	187.5	173.7	178.8	195.1	207.8	210.3	221.8	239.5
Expenses
+ Cost of Materials Consumed	16.3	16.0	18.8	18.8	23.0	20.9	22.2	21.4	24.3	24.0	24.9	25.6
+ Employee Benefit Expense	21.8	23.0	24.5	27.4	27.8	28.6	28.4	31.6	32.3	33.0	33.8	37.5
+ Finance Costs	5.9	6.1	6.2	6.3	6.5	6.8	7.2	7.5	7.8	8.6	9.3	11.0
+ Depreciation & Amortisation	13.7	14.5	16.3	16.6	16.8	18.3	18.8	20.9	22.3	24.3	24.3	25.1
+ Other Expenses	43.3	41.4	48.8	48.9	56.1	52.4	53.8	61.5	63.2	62.1	65.1	69.4
Total Expenses	101.0	101.0	114.6	117.9	130.3	127.0	130.4	142.9	149.8	152.1	157.5	168.6
EBITDA	57.4	52.3	63.1	61.2	76.0	67.1	68.9	73.5	81.8	86.1	95.5	98.5
EBIT	43.7	37.8	46.8	44.6	59.1	48.8	50.0	52.6	59.6	61.7	71.2	73.4
Profit
PBT before Exceptional Items	44.6	36.8	43.9	41.9	57.2	46.7	48.4	52.2	58.0	58.2	64.3	70.9
+ Exceptional Items	0.0	-2.1	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	0.0	0.0	0.0
Pretax Income	44.6	34.8	43.9	41.9	57.2	46.7	47.4	52.2	58.0	58.2	64.3	70.9
+ Current Tax	8.7	9.2	8.2	9.6	12.8	9.3	9.4	11.6	12.6	11.7	14.8	16.6
+ Deferred Tax	2.3	-0.5	2.0	0.8	2.2	2.1	3.1	2.0	2.1	3.4	1.5	1.3
Tax Expense	11.0	8.8	10.2	10.4	15.1	11.4	12.5	13.6	14.7	15.0	16.3	17.8
Net Income	33.6	26.0	33.7	31.5	42.1	35.3	34.9	38.6	43.3	43.2	47.9	53.1
+ Net Income — Continuing Ops	33.6	26.0	33.7	31.5	42.1	35.3	34.9	38.6	43.3	43.2	47.9	53.1
+ Other Comprehensive Income	0.0	0.0	-0.3	-0.0	-0.0	-0.0	0.1	-0.1	0.3	-0.0	0.5	0.2
Total Comprehensive Income	33.6	26.0	33.4	31.5	42.1	35.3	35.0	38.5	43.6	43.1	48.4	53.3
Net Income to Common	33.3	25.8	33.5	31.3	41.9	35.2	34.6	38.3	43.3	43.2	47.9	53.1
Minority Interest	0.3	0.2	0.2	0.2	0.2	0.1	0.2	0.3	0.0	0.0	0.0	0.0
Per Share
Basic EPS	3.26	2.53	3.27	3.06	4.09	3.42	3.38	3.76	4.21	4.20	4.66	5.16
Diluted EPS	3.25	2.52	3.26	3.05	4.08	3.42	3.37	3.75	4.20	4.19	4.65	5.15
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.1	-0.1	0.3	-0.0	0.5	0.2
+ Items NOT to be Reclassified to P&L	0.1	0.1	-0.3	-0.0	-0.0	-0.0	0.1	-0.1	0.4	-0.0	0.6	0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	-0.0	0.1	-0.0	0.2	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	-0.1	-0.0	-0.0	-0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	33.4	25.9	33.2	31.3	41.9	35.1	34.7	38.3	43.6	43.1	48.4	53.3
Comprehensive Income — Non-controlling Interests	0.3	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.0	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.26	2.53	3.27	3.06	4.09	3.42	3.38	3.76	4.21	4.20	4.66	5.16
Diluted EPS — Continuing Operations	3.25	2.52	3.26	3.05	4.08	3.42	3.37	3.75	4.20	4.19	4.65	5.15
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	122.5	116.7	136.4	137.5	160.0	148.1	151.1	166.6	177.2	181.2	194.4	205.4
Gross Margin %	88.23	87.95	87.88	87.99	87.43	87.66	87.21	88.61	87.93	88.29	88.64	88.92
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	44.6	36.8	43.9	41.9	57.2	46.7	48.4	52.2	58.0	58.2	64.3	70.9
− Exceptional Items (reconciliation)	0.0	-2.1	0.0	0.0	0.0	0.0	-1.0	0.0	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	33.6	27.5	33.7	31.5	42.1	35.3	35.6	38.6	43.3	43.2	47.9	53.1
EPS Adj	3.26	2.68	3.27	3.06	4.09	3.42	3.45	3.76	4.21	4.20	4.66	5.16
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	10.2	10.2	10.2	10.3	10.3	10.3	10.3	10.3	10.3	10.3	10.3	10.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Vijaya Diagnostic Centre Q2 FY27 results date

Vijaya Diagnostic Centre (NSE: VIJAYA) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹53.1 crore, up 38.5% from ₹38.3 crore in Q1 FY26 and up 10.8% from ₹47.9 crore in Q4 FY26. Revenue from operations was ₹231 crore, up 22.8% year on year and up 5.3% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 4 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 28 Oct
Q1 FY27 net profit: ₹53.1 Cr+38.5% vs Q1 FY26+10.8% vs Q4 FY26
Q1 FY27 revenue: ₹231 Cr+22.8% vs Q1 FY26+5.3% vs Q4 FY26
Q1 FY27 operating margin: 31.8%+3.8 pts vs Q1 FY26−0.7 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹43.3 CrRevenue ₹202 Cr
Q1 FY27 EPS (basic): ₹5.16

Questions

When will Vijaya Diagnostic Centre announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 4 November 2025.

What were Vijaya Diagnostic Centre's Q1 FY27 results?

Consolidated net profit was ₹53.1 crore, up 38.5% from ₹38.3 crore in Q1 FY26 and up 10.8% from ₹47.9 crore in Q4 FY26. Revenue from operations was ₹231 crore, up 22.8% year on year and up 5.3% from the previous quarter.

What was Vijaya Diagnostic Centre's net profit in FY26?

Consolidated net profit was ₹173 crore in FY26 (April 2025–March 2026), up 20.9% from ₹143 crore in FY25. It was ₹119 crore in FY24 and ₹84.6 crore in FY23: up 104.4% over three years, 26.9% a year on average.

What will Vijaya Diagnostic Centre's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹43.3 crore and revenue from operations ₹202 crore. The latest quarter, Q1 FY27, had a net profit of ₹53.1 crore and revenue of ₹231 crore.

How has Vijaya Diagnostic Centre's profit changed over the last four quarters?

Net profit by quarter: ₹43.3 crore in Q2 FY26, ₹43.2 crore in Q3 FY26, ₹47.9 crore in Q4 FY26 and ₹53.1 crore in Q1 FY27. That is ₹187 crore over the four quarters, up 24.9% from ₹150 crore in the four quarters before. Revenue from operations: ₹202 crore, ₹205 crore, ₹219 crore and ₹231 crore.

What was Vijaya Diagnostic Centre's revenue in FY26?

Revenue from operations was ₹814 crore in FY26 (April 2025–March 2026), up 19.5% from ₹681 crore in FY25. It was ₹548 crore in FY24 and ₹459 crore in FY23: up 77.3% over three years, 21.0% a year on average.

Where do these Vijaya Diagnostic Centre figures come from?

From Vijaya Diagnostic Centre's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.